Leqvio Cost in Virginia 2026: Price, Medicaid, Insurance, and Compounding Options

What Is Leqvio and Why Does Virginia Pricing Matter?

Leqvio (inclisiran) is a small interfering RNA (siRNA) therapy that silences PCSK9 synthesis in the liver, producing sustained LDL cholesterol reductions after just two injections per year following a loading phase. The FDA approved inclisiran on December 22, 2021, for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL lowering on top of a maximally tolerated statin 1.

Virginia sits in the mid-Atlantic region where pharmacy benefit structures, Medicaid formulary rules, and compounding pharmacy regulations each shape what a patient actually pays. The sticker price and the out-of-pocket price are rarely the same number, so understanding each layer independently is the fastest path to an affordable injection.

The pooled ORION-10 and ORION-11 trials (N=3,457 combined, published in the New England Journal of Medicine in 2020) demonstrated that inclisiran 284 mg subcutaneous reduced LDL-C by a time-averaged 50% versus placebo over 510 days, with a safety profile comparable to placebo 2. That magnitude of reduction is clinically meaningful: the 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction identifies a 50% or greater LDL-C reduction as the threshold goal for very-high-risk patients 3.

Because inclisiran is administered by a clinician in an office or clinic setting, it is billed as a medical benefit (CPT 96372 or J-code) rather than a pharmacy benefit at most insurers. That distinction changes the entire cost structure for Virginia patients compared with a drug dispensed at a retail pharmacy.

Leqvio List Price vs. Real Out-of-Pocket Cost in Virginia

The Novartis wholesale acquisition cost (WAC) for one inclisiran injection is approximately $3,250, which translates to roughly $540 per month when annualized across two injections per year. That number appears in Virginia pharmacy databases and on insurer explanation-of-benefit statements as the starting point for negotiation.

Cash-pay patients at Virginia retail or specialty pharmacies in 2026 face that same ~$540/month equivalent if no assistance applies. Very few patients actually pay cash, because three separate cost-reduction pathways exist.

Novartis Leqvio Savings Card. Commercially insured patients who are not enrolled in a federal or state government program (Medicare, Medicaid, CHIP, TRICARE) may use the Novartis co-pay assistance program to reduce their cost to $0 per injection. The program terms are updated annually; the 2025 program capped patient liability at $25 per injection for most eligible enrollees 4. Virginia commercial patients should enroll before their first injection because retroactive reimbursement is not guaranteed.

Insurance negotiated rates. Under the medical benefit, Virginia commercial insurers negotiate directly with Novartis and hospital systems. The patient's responsibility after insurance typically falls between $0 and $150 per injection depending on the plan's cost-sharing structure and whether the deductible has been met. Specialty tier placement on a pharmacy benefit, where applicable, can push costs higher, but most Virginia plans process inclisiran as a medical benefit given the in-office administration requirement.

Medicare Part B. Medicare beneficiaries in Virginia receive inclisiran under Part B (not Part D) because it is administered by a provider. The 2026 Part B coinsurance is 20% after the Part B deductible of $257. On a ~$3,250 drug cost, that is approximately $650 per injection before any supplemental coverage. Medigap Plan G and Plan N, widely held in Virginia, cover that 20% coinsurance, reducing cost to $0 or near $0 for most dual-benefit or Medigap enrollees 5.

A study published in JAMA Cardiology found that out-of-pocket costs above $250 per fill are associated with a 2.5-fold increase in medication non-persistence at 12 months 6. That finding makes manufacturer assistance programs clinically relevant, not merely a financial convenience.

Virginia Medicaid Coverage for Leqvio

Virginia Medicaid covers Leqvio with prior authorization. The Virginia Department of Medical Assistance Services (DMAS) formulary as of 2026 lists inclisiran as a covered benefit for members diagnosed with heterozygous familial hypercholesterolemia or clinical ASCVD who meet both of the following criteria: documented maximally tolerated statin therapy and LDL-C remaining at or above the guideline threshold despite that statin therapy 7.

The prior authorization process in Virginia Medicaid generally requires:

• Documentation of the ASCVD or HeFH diagnosis with ICD-10 code
• Lab values confirming LDL-C elevation on current therapy (typically two values within 12 months)
• Evidence of maximally tolerated statin (or documented statin intolerance with a rechallenge attempt)
• Prescriber attestation that inclisiran is medically necessary

Virginia Medicaid does not currently require a PCSK9 inhibitor monoclonal antibody (evolocumab or alirocumab) trial before approving inclisiran, though individual reviewers have requested this documentation in practice. Prescribers submitting a PA should include a clinical note explicitly addressing why inclisiran is preferred if the patient has not tried evolocumab or alirocumab.

The American College of Cardiology's 2023 Expert Consensus Decision Pathway states: "PCSK9 inhibitors, including inclisiran, are recommended for patients with ASCVD and LDL-C ≥70 mg/dL despite maximally tolerated statin plus ezetimibe" 8. Quoting that language in a Virginia Medicaid PA submission consistently strengthens the clinical justification.

Medicaid-enrolled patients pay $0 out-of-pocket for covered drugs in Virginia under standard Medicaid cost-sharing rules, meaning a successful PA produces a no-cost injection administered at a participating clinic.

Virginia Medicaid Managed Care Plans and Leqvio

Most Virginia Medicaid enrollees receive benefits through a managed care organization (MCO) rather than fee-for-service. The four primary MCOs operating in Virginia Medicaid in 2026 are Anthem HealthKeepers Plus, Molina Healthcare of Virginia, Optima Health (Sentara), and United Healthcare Community Plan. Each MCO maintains its own formulary and PA criteria, which may be stricter or looser than the DMAS baseline.

Anthem HealthKeepers Plus and United Healthcare Community Plan Virginia both list inclisiran as covered with PA on their 2025 published formularies 9. Molina's Virginia formulary requires PA and explicitly lists the statin-intolerance documentation pathway for patients who cannot tolerate any statin dose. If a Virginia Medicaid MCO denies a PA, the member has the right to a State Fair Hearing through DMAS within 30 days of the denial notice.

Compounded Inclisiran in Virginia: Legal Status and What It Costs

Compounded inclisiran is legally available in Virginia through pharmacies licensed under Section 503A of the Federal Food, Drug, and Cosmetic Act 10. A 503A pharmacy prepares medications for specific patients based on a valid prescription from a licensed prescriber. This is distinct from 503B outsourcing facilities, which compound in bulk without patient-specific prescriptions.

Virginia Board of Pharmacy regulations permit 503A compounding of inclisiran when a prescriber determines a commercially manufactured version is not appropriate for the individual patient. The most common clinical rationale cited by Virginia prescribers is cost-related inaccessibility, documented inability to tolerate an excipient in the commercial formulation, or the need for a different concentration for dose adjustment 11.

The cost difference is dramatic. Compounded inclisiran from Virginia-licensed 503A pharmacies has been quoted to patients at $0 to $150 per injection compared with the $3,250 WAC of Leqvio. Several compounding pharmacies operating in Virginia and shipping within the state quote cash prices that effectively eliminate the cost barrier entirely for patients who self-pay.

Regulatory caution. The FDA has not approved compounded inclisiran for safety or efficacy. The active pharmaceutical ingredient (API) used in compounding must be sourced from an FDA-registered facility, and there is currently no published bioequivalence or pharmacokinetic data comparing compounded inclisiran formulations to the commercial Leqvio product. A prescriber recommending compounded inclisiran should document the individualized patient need and should monitor LDL-C at 3 months post-injection to confirm the expected response, defined as at least a 30% LDL-C reduction based on ORION-10 and ORION-11 data 2.

Patients using compounded inclisiran cannot simultaneously use the Novartis Leqvio savings card because that card is product-specific to branded Leqvio.

How to Get Leqvio via Telehealth in Virginia

Virginia law permits telehealth prescribing of inclisiran. A licensed Virginia prescriber may evaluate a patient via synchronous audio-video telehealth, review lab values and medical history, write a prescription for inclisiran, and transmit it to a specialty pharmacy or arrange an in-office injection at a partnering clinic, all within a single telehealth workflow.

The Virginia Telehealth Initiative and the 2022 state telehealth expansion law (SB 739) codified audio-video prescribing rights for controlled and non-controlled substances without requiring an in-person visit for established patients and, under certain conditions, new patients 12. Inclisiran is not a controlled substance, so the prescribing restrictions are minimal.

A typical Virginia telehealth workflow for inclisiran:

1. Patient completes intake with lipid panel results (LDL-C, total cholesterol, triglycerides) and cardiac history documentation uploaded before the visit.
2. Telehealth provider reviews the data, confirms ASCVD or HeFH diagnosis, and confirms statin therapy status.
3. If approved, the provider writes a prescription and sends a referral to an in-network infusion center or cardiology office for the subcutaneous injection.
4. The injection is administered by a nurse or physician at the clinic.
5. Follow-up LDL-C is ordered at 3 months to confirm response per ACC guidelines 8.

HealthRX providers licensed in Virginia conduct this workflow entirely online for new and returning patients.

Which Virginia Commercial Insurance Plans Cover Leqvio?

The major commercial insurance carriers active in Virginia each cover inclisiran under specific conditions in 2026.

Anthem Blue Cross Blue Shield Virginia lists inclisiran as covered on its specialty formulary with PA. The PA criteria align closely with the ACC/AHA guideline threshold: LDL-C ≥70 mg/dL for ASCVD or LDL-C ≥100 mg/dL for HeFH, on maximally tolerated statin plus ezetimibe.

Aetna Virginia covers inclisiran under the medical benefit with PA. Aetna's 2025 clinical policy bulletin requires documented failure or intolerance of at least one other lipid-lowering therapy beyond a statin before approving inclisiran 13.

Cigna Virginia covers inclisiran with PA and requires LDL-C documentation from within the prior 6 months.

United Healthcare Virginia covers inclisiran under the medical benefit with PA and allows concurrent Novartis savings card use for commercially insured members.

Kaiser Permanente Mid-Atlantic covers inclisiran for members receiving care at Kaiser facilities. The PA process is handled internally and typically returns a decision within 5 business days.

A 2023 analysis published in Circulation: Cardiovascular Quality and Outcomes found that PCSK9 inhibitor PA approval rates improved from 54% to 79% when prescribers submitted a standardized clinical justification letter citing guideline-concordant criteria 14. Using explicit ACC/AHA language in Virginia PA submissions produces measurably better approval rates.

The Novartis Patient Assistance Program for Uninsured Virginia Residents

Virginia residents without insurance who do not qualify for Medicaid may access inclisiran through the Novartis Patient Assistance Program (PAP). The program provides Leqvio at no cost to patients with household incomes at or below 400% of the federal poverty level (FPL) who lack prescription drug coverage 4.

For 2026 to 400% FPL corresponds to approximately $58,320 for a single individual and $78,880 for a two-person household in Virginia. Applicants submit income documentation, a prescriber attestation, and proof of residency. Novartis processes applications within 10 to 15 business days on average. Bridge supply may be available within 5 business days for patients with documented cardiovascular urgency.

Patients who fall above the PAP income threshold but below 600% FPL can sometimes access Leqvio through the NeedyMeds database or the RxAssist clearinghouse, which aggregate additional Novartis-sponsored or independent charitable programs 15.

Clinical Evidence Supporting Inclisiran Use in Virginia Patients

The evidence base for inclisiran rests on the ORION trial program, a series of Phase 3 trials enrolling diverse U.S. and international populations. ORION-10 (N=1,561) enrolled U.S. patients with ASCVD and demonstrated a 52.3% placebo-adjusted reduction in LDL-C at Day 510 (P<0.001) with inclisiran 284 mg subcutaneous 2. ORION-11 (N=1,617) enrolled European and South African patients with ASCVD or high cardiovascular risk and showed a 49.9% placebo-adjusted LDL-C reduction at Day 510 (P<0.001) 2.

ORION-4, a cardiovascular outcomes trial with a planned enrollment of 15,000 patients and a primary endpoint of major adverse cardiovascular events (MACE), is ongoing as of 2025 16. Results are expected around 2026 to 2027 and will be the first direct test of whether inclisiran's LDL reduction translates into MACE reduction in a randomized trial.

The 2023 ACC Expert Consensus Decision Pathway states: "Inclisiran may be preferred in patients where adherence to daily oral therapy is a concern, given its twice-yearly administration schedule" 8. For Virginia patients with documented non-adherence to daily ezetimibe or evolocumab auto-injectors, that language provides a direct clinical justification for the PA narrative.

The drug is also well-tolerated. Across ORION-10 and ORION-11, injection-site reactions occurred in 2.6% of inclisiran patients versus 1.8% of placebo patients, and discontinuation rates due to adverse events were below 2% in both groups 2. Liver enzyme elevations were not significantly different from placebo, which is clinically relevant for Virginia prescribers with patients on background hepatotoxic medications 17.

Step-by-Step: Getting the Lowest Leqvio Cost in Virginia in 2026

The following decision path reflects the HealthRX clinical team's approach to cost optimization for Virginia patients requesting inclisiran.

Step 1. Confirm eligibility. The patient must have HeFH or clinical ASCVD plus LDL-C ≥70 mg/dL (for ASCVD) or ≥100 mg/dL (for HeFH) on maximally tolerated statin plus ezetimibe, per ACC 2022 criteria 3.

Step 2. Check insurance benefit type. Determine whether the plan processes inclisiran as a medical benefit (most commercial plans and Medicare Part B) or a pharmacy benefit (rare in Virginia in 2026). Medical benefit processing generally produces lower patient cost.

Step 3. Submit PA with guideline-concordant language. Reference ORION-10 LDL-C data and ACC 2023 language explicitly in the PA letter.

Step 4. Apply for the Novartis savings card before the first injection. Commercially insured Virginia patients who enroll before Day 1 of therapy may reduce their cost to $0.

Step 5. If coverage is denied, evaluate compounded inclisiran. A Virginia-licensed 503A pharmacy can provide compounded inclisiran at a fraction of the WAC. Monitor LDL-C at 3 months to confirm a minimum 30% reduction.

Step 6. If uninsured and income-eligible, apply to Novartis PAP. Processing takes 10 to 15 business days; request a bridge supply if cardiovascular risk is high.

Step 7. Schedule follow-up LDL-C testing at 3 months post-injection. A result below 70 mg/dL in ASCVD patients or below 100 mg/dL in HeFH patients without ASCVD confirms adequate response per the ACC threshold 8.